Caricamento...
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (doceta...
Salvato in:
| Pubblicato in: | Ther Adv Urol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4580096/ https://ncbi.nlm.nih.gov/pubmed/26445599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215592288 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|